ArticleBritish journal of clinical pharmacology2008
Effect of theophylline on the rate of moderate to severe exacerbations among patients with chronic obstructive pulmonary disease.
Article in British journal of clinical pharmacology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 2 syntheses or guidelines pooled it, 37 citations in OpenAlex.
- Low-dose theophylline in addition to ICS therapy in COPD patients: A systematic review and meta-analysis.PloS one · 2021Pooled it
- Association between lung function and exacerbation frequency in patients with COPD.International journal of chronic obstructive pulmonary disease · 2010Pooled it
- Trial
- Caffeine Synthesis and Its Mechanism and Application by Microbial Degradation, A Review.Foods (Basel, Switzerland) · 2023Review
- Workshop report: Toward the development of a human whole stool reference material for metabolomic and metagenomic gut microbiome measurements.Metabolomics : Official journal of the Metabolomic Society · 2020Article
- Article
- In reply.Deutsches Arzteblatt international · 2014Article
- The effects of theophylline on hospital admissions and exacerbations in COPD patients: audit data from the Bavarian disease management program.Deutsches Arzteblatt international · 2014Article
- N-acetylcysteine instead of theophylline in patients with COPD who are candidates for elective off-pump CABG surgery: Is it possible in cardiovascular surgery unit?Saudi journal of anaesthesia · 2013Article
- The asthma-chronic obstructive pulmonary disease overlap syndrome: pharmacotherapeutic considerations.Expert review of clinical pharmacology · 2013Review
- Clinical outcomes of theophylline use as add-on therapy in patients with chronic obstructive pulmonary disease: A propensity score matching analysis.Chronic respiratory diseaseArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo determine the effectiveness of theophyllines in real clinical practice on moderate to severe exacerbations.
methodsA cohort of 36,492 chronic obstructive pulmonary disease (COPD) patients aged > or =50 years was reconstructed from the health administrative databases of the province of Quebec, Canada, between 1 January 1995 and 31 December 2002 to compare users of theophyllines with users of inhaled corticosteroids (ICS) and users of long-acting beta(2)-agonists (LABA) on their rate of moderate to severe COPD exacerbations.
resultsUsers of theophyllines were found to be less likely than users of LABA [crude rates 84 vs. 91 per 100 patient-years, adjusted rate ratio (RR) 0.89, 95% confidence interval (CI) 0.84, 0.95] and users of theophyllines plus ICS were found to be less likely than users of LABA plus ICS (crude rates 114 vs. 112 per 100 patient-years, adjusted RR 0.89, 95% CI 0.87, 0.92) to have moderate to severe COPD exacerbations. Users of theophyllines were found to be more likely than users of ICS to have a COPD exacerbation (crude rates 84 vs. 77 per 100 patient-years, adjusted RR 1.07, 95% CI 1.04, 1.10), and this association was even stronger among patients who had at least three exacerbations in the year prior to cohort entry (crude rates 273 vs. 213 per 100 patient-years, adjusted RR 1.28, 95% CI 1.19, 1.38).
conclusionThe use of theophyllines was found to be associated with a reduction in the rate of COPD exacerbations among all COPD patients, but to be less effective than ICS among patients with frequent exacerbations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.